Learn the Role of Vyepti for Migraine Prevention

December 2022

Vyepti (eptinezumab) will join Aimovig (erenumab), Ajovy (fremanezumab), and Emgality (galcanezumab), to PREVENT migraine in adults.

All of these meds decrease migraine frequency by limiting vasodilation by blocking calcitonin gene-related peptide (CGRP).

They’ll be saved for when oral meds to prevent migraine...such as propranolol or topiramate...aren’t enough.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Pediatrics Help Find Options During the Acetaminophen and Ibuprofen Shortage
Practice Get Your Pharmacy “Inspection-Ready”
Cough & Cold Stay Alert for Common Errors With OTC Cough and Cold Meds
Cholesterol Watch for Leqvio, a New Med for High Cholesterol
Dispensing Don’t Let Your Patients Get Expired Meds
Cardiology Clear Up Confusion With Calcium Channel Blockers
Education and Training Be Ready to Navigate Challenges With Trainees
Migraine Learn the Role of Vyepti for Migraine Prevention
Psoriasis Prevent Mix-Ups With the Multitude of Meds for Psoriasis